EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease

Mezin Öthman iD, Dag Nyholm iD

Movement Disorders Clinical Practice · 2024-12 · 11 (12) · 1609-1612

DOI: 10.1002/mdc3.14240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 24.10.2024. Verfasst von Mezin Öthman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Carbidopa, Catechols. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Britannia Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa‐entacapone‐carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long‐term data are lacking.

Objectives

To study long‐term data on LECIG treatment.

Methods

A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.

Results

Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9–30) and 3.6 (3.1–4.0) years, respectively, whereas health‐related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8‐item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ‐5D visual analogue scale scores of 65 (10; n = 7).

Conclusions

LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaCarbidopaCatecholsAntiparkinson AgentsGelsDrug CombinationsNitrilesHumansMaleFemaleAgedMiddle AgedRetrospective StudiesQuality of LifeFollow-Up StudiesTreatment OutcomeAged, 80 and overSweden

Stichwörter der Autor:innen

Parkinson's diseasecarbidopaentacaponeinfusion pump.levodopa infusion therapy

Substanzen

LevodopaCarbidopaCatecholsAntiparkinson AgentsGelsDrug CombinationsNitrilesentacaponecarbidopa, levodopa drug combination

Autor:innen und Institutionen

  • Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Mezin Öthman, Dag Nyholm

Förderung

  • Britannia Pharmaceuticals

Zitieren

APA

Öthman, M., & Nyholm, D. (2024). A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease. Movement Disorders Clinical Practice, 11(12), 1609-1612. https://doi.org/10.1002/mdc3.14240

Vancouver

Öthman M, Nyholm D. A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease. Movement Disorders Clinical Practice. 2024;11(12):1609-1612. doi:10.1002/mdc3.14240

BibTeX
@article{thman2024,
  author = {Öthman, Mezin and Nyholm, Dag},
  title = {A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  volume = {11},
  number = {12},
  pages = {1609--1612},
  doi = {10.1002/mdc3.14240}
}
Kostenlos starten →